This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Ribavirin
From Proteopedia
| Line 1: | Line 1: | ||
| - | 1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide <ref>DOI: 10.1093/jac/dki405 </ref> | + | 1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide <ref>DOI: 10.1093/jac/dki405 </ref> |
<StructureSection load='1stp' size='340' side='right' caption='Caption for this structure' scene=''> | <StructureSection load='1stp' size='340' side='right' caption='Caption for this structure' scene=''> | ||
This is a default text for your page '''Ribavirin'''. Click above on '''edit this page''' to modify. Be careful with the < and > signs. | This is a default text for your page '''Ribavirin'''. Click above on '''edit this page''' to modify. Be careful with the < and > signs. | ||
| Line 5: | Line 5: | ||
== Overview == | == Overview == | ||
| - | Ribavirin was first synthesized in 1970 by ICN Pharmaceuticals (now “Valent International Pharmaceuticals”). In 1986, its first major use was the treatment of RSV (respiratory syncitial virus) infections in pediatric patients | + | Ribavirin was first synthesized in 1970 by ICN Pharmaceuticals (now “Valent International Pharmaceuticals”) <ref>DOI: 10.1093/jac/dki405 </ref>. In 1986, its first major use was the treatment of RSV (respiratory syncitial virus) infections in pediatric patients, but since its FDA approval in 1998, it has primarily been used as a component in treating Hepatitis C.<ref>DOI: 10.1093/jac/dki405 </ref> The treatment was modified and approved in 2002 by the FDA by combining it with interferon alfa2b <ref>DOI: 10.1093/jac/dki405 </ref>. |
== Structure & Function == | == Structure & Function == | ||
Revision as of 02:16, 16 November 2016
1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide [1]
| |||||||||||
References
- 1. Gish, R. G. (2005, November 17). Treating HCV with ribavirin analogue and ribavirin-like molecules. Journal of Antimicrobial Chemotherapy, 1-6. doi:10.1093/jac/dki405
3. Chung, R.T., Gale, M.J., Polyak, S.J., Lemon, S.M., Liang, T.J., & Hoofnagle, J.H. (2008). Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop. Hepatology, 47 (1), 306-320. doi: 10.1002/hep.22070 4. National Heart, Lung and Blood Institute. (2016, September 26). Pneumonia. Retrieved from https://www.nhlbi.nih.gov/health/health-topics/topics/pnu
Proteopedia Page Contributors and Editors (what is this?)
Jamie Costa, Edmond R Atalla, Katherine Reynolds, Taylor H. Derby, Shannon Shaughnessy, Alexander Berchansky
